Chronic Aspergillosis Treatment Market To Worth Over US$ 4,056.4 Million with 4.8% CAGR up to 2028 | Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd.

By prince On Aug 23, 2022 3 0

Chronic Aspergillosis Treatment Market

A significant item pipeline for the treatment of chronic aspergillosis would be considered normal to propel the development of the global chronic aspergillosis treatment market. For instance, on July 2, 2020, Merck Sharp and Dohme Corp., a pharmaceutical organization, initiated a phase II open-label, non-comparative clinical preliminary review of the safety and efficacy of Posaconazole (POS, MK-5592) in pediatric members aged two to less than 18 years with invasive aspergillosis. The review is estimated to be completed by December 2021.

Click Here to Get a Sample Copy (Exclusive Offer: Up to 30% Discount for A Limited Time) @ https://www.coherentmarketinsights.com/insight/request-sample/4611

Impact of the COVID-19 pandemic on the market

The COVID-19 pandemic caused significant interruptions to clinical preliminary execution in the U.S., affecting key stakeholders across the business. Investigative site capabilities experienced upheaval, driven by staff vacations, social-removing conventions, monetary losses, and concerns over patient safety. Backers, CROs, and other associations that help drug development shifted to remote workplaces. An estimated 80% of non-COVID-19 preliminaries were stopped or interrupted as a result of the COVID-19 pandemic. For instance, an April 2020 review suggests that investigative sites demonstrated flexibility and ingenuity in embracing new approaches to cope with challenges presented by the COVID, with over a portion of investigative sites changing to virtual approaches to interact with patients. More recently, follow-up studies performed in August 2020 identified the persistent effect of COVID, with over 60% reporting an ‘average’ or greater level of effect on continuous preliminaries and commencement of new preliminaries. Respondents specifically highlighted challenges in patient enrollment and recruitment. There are all out 6,114 clinical preliminaries suspended/withdrawn or terminated from September 1, 2019, till October 13, 2020. Out of which, 1,008 clinical preliminaries were suspended due to the COVID-19 pandemic which accounted for 16% of complete preliminaries suspended/withdrawn or terminated and 84% of preliminaries because of other reasons. Among 1,008 preliminaries, 77% of preliminaries were suspended, 16% of preliminaries were terminated, and 7% of preliminaries were withdrawn. Preliminaries that are in Phase II are for the most part affected by this pandemic circumstance. This has potentially extended or pushed the completion date ahead and along these lines, the send-off of new items. Moreover, as indicated by Medidata Solutions, Inc. on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for continuous clinical preliminaries and 43% of the respondents have postponed their studies.

Moreover, increasing government initiatives for diagnosing and treatment of chronic infection are expected to drive the development of the global chronic aspergillosis treatment market. For instance, in 2016, the Infectious Diseases Society of America (IDSA) published new guidelines for the analysis and treatment of infections due to Aspergillus species. The document offers guidance on non-culture-based identification of Aspergillus infections and rejects the use of blend anti-fungal therapy for essential management. The guidelines additionally define the therapy of isavuconazole, a new U.S. Food and Drug Administration (FDA) approved antifungal drug in March 2015 to treat mucormycosis and aspergillosis.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4611

Key Takeaways of the Global Chronic Aspergillosis Treatment Market:

The global chronic aspergillosis treatment market is expected to exhibit a CAGR of 4.8% during the forecast period due to heavy R&D subsidizing by significant companies as key companies operating in the market bringing assets up in order to expand their research and development activities for the development of novel therapeutics for the treatment of chronic aspergillosis. For instance, in May 2021, Pulmocide Ltd. announced that the organization had raised US$ 92 million in an oversubscribed Series C funding round
Among distribution channels, the one related to hospital pharmacies is estimated to witness the largest market share in the global chronic aspergillosis treatment market over the forecast period. An increasing number of patients suffering from chronic aspergillosis, as most would consider normal drives demand for hospital organization of patients for the treatment of chronic aspergillosis. For instance, as indicated by the CDC, it is assessed that around 1% to 15% individuals suffering from cystic fibrosis are mainly to be impacted by ABPA. One review calculated that 2.5% of grown-ups who have asthma likewise have ABPA, which is around 4.8 million people worldwide. Of these around 400,000 likewise have CPA.
Among the regions, North America is estimated to stand firm on its predominant footing in the global chronic aspergillosis treatment market is increasing number of aspergillosis cases in the United States is expected to boost the development of the market. For instance, as indicated by the article published by the Center for Disease Control and Prevention, from 2000-to 2013 the number of hospitalizations related to invasive aspergillosis in the U.S. increased by an average of 3% per year. As indicated by the same source, around 15,000 aspergilli are associated with hospitalizations that occurred in the U.S. in 2014, at an estimated cost of US$ 1.2 billion.
Key players operating in the global chronic aspergillosis treatment market include Novartis International AG, Teva Pharmaceutical Industries Ltd., F2G Ltd, PULMATRiX, Inc., GlaxoSmithKline plc., Mayne Pharma Group Limited, Glenmark Pharmaceuticals, Merck & Co., Inc., Mylan N.V., Johnson & Johnson, Pulmocide Ltd., Pfizer Inc., Abbott Laboratories, and Astellas Pharma Inc.

Grab the Offer Mentioned Above Global Outlook and Forecast 2022-2028 @ https://www.coherentmarketinsights.com/promo/buynow/4611

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug Class
  - Market Snapshot, By Disease Type
  - Market Snapshot, By Distribution Channel
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunity
- Impact Analysis
- Key Developments
- Market Trends
- Epidemiology
- Incidence rate of Chronic Aspergillosis (Asthma, COPD, Bronchiectasis, and others)
- Product Approvals/Launches
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Merger, Acquisition & Agreements
- Treatment Algorithm
Global Chronic Aspergillosis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
- Supply and Demand Analysis
- COVID-19 Impact on Clinical Trials
- Economic Impact
Global Chronic Aspergillosis Treatment Market, By Drug Class, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2017 – 2028
  - Segment Trends
- Corticosteroids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Anti-fungal Drugs
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Global Chronic Aspergillosis Treatment Market, By Disease Type, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2017 – 2028
  - Segment Trends
- Simple Aspergilloma
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Chronic Cavitary Pulmonary Aspergillosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Chronic Fibrosing Pulmonary Aspergillosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Subacute Invasive Aspergillosis
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Allergic Bronchopulmonary Aspergillosis [ABPA]
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Severe Asthma With Fungal Sensitization [SAFS]
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Global Chronic Aspergillosis Treatment Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Introduction
  - Market Share Analysis, 2021 and 2028 (%)
  - Y-o-Y Growth Analysis, 2017 – 2028
  - Segment Trends
    - Hospital Pharmacies
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    - Retail Pharmacies and Drug Store
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
    - E-commerce
      - Introduction
      - Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)

View Press Release: https://www.coherentmarketinsights.com/press-release/chronic-aspergillosis-treatment-market-3861

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Source link